I am a medical oncologist with clinical expertise in the diagnosis and treatment of women with gynecologic malignancies including ovarian, uterine, and cervical cancers as well as other less-common tumors.
My clinical research focuses on developing novel treatments and improving treatment strategies for women with gynecologic malignancies. I have a particular interest in the use of targeted therapies for the treatment of recurrent ovarian cancer. I have developed, and serve as the principal investigator for, ongoing clinical trials in this area.
- Clinical Expertise: Treatment of Ovarian, Endometrial, and Cervical Cancers; Treatment of rare tumor types, including low-grade serous ovarian cancer; Clinical Trials
- Languages Spoken: English
- Education: MD, Duke University School of Medicine
- Residencies: Massachusetts General Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Rachel N. Grisham
- A Phase IB Study of MEK162 plus Paclitaxel in Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- A Phase II Study of Enzalutamide in Patients with Advanced or Recurrent Androgen Receptor-Positive Ovarian Cancer
- A Phase III Study of MEK162 versus Standard Chemotherapy in Patients with Recurrent or Persistent Low-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: The MILO Study